{"id":"gemigliptin","rwe":[{"pmid":"41804593","year":"2026","title":"Effect of anti-tuberculosis drugs on the pharmacokinetics and pharmacodynamics of novel antidiabetic drugs: A scoping review.","finding":"","journal":"Pulmonology","studyType":"Clinical Study"},{"pmid":"41327925","year":"2025","title":"Gemigliptin Alleviates Succinate Induced Endoplasmic Reticulum Stress and Activation of Hepatic Stellate Cells.","finding":"","journal":"Journal of Korean medical science","studyType":"Clinical Study"},{"pmid":"41084226","year":"2025","title":"Pharmacokinetics and Safety of Fixed-Dose Versus Separate Enavogliflozin/Gemigliptin Combinations, and Food Effect on Enavogliflozin in Healthy Korean Subjects.","finding":"","journal":"Clinical and translational science","studyType":"Clinical Study"},{"pmid":"40633785","year":"2025","title":"Repositioning gemigliptin for the alleviation of thioacetamide-induced liver fibrosis in rats: Targeting TLR4/MAPK, SIRT1/AMPK/Nrf2, PI3K/AKT/mTOR axis and apoptosis.","finding":"","journal":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","studyType":"Clinical Study"},{"pmid":"39910751","year":"2025","title":"Effectiveness of gemigliptin on risk of major adverse kidney events in people with type 2 diabetes: A Korean cohort study.","finding":"","journal":"Diabetes, obesity & metabolism","studyType":"Clinical Study"}],"tags":[{"label":"gemigliptin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Dipeptidyl peptidase 4","category":"target"},{"label":"DPP4","category":"gene"},{"label":"DPP9","category":"gene"},{"label":"A10BD18","category":"atc"},{"label":"Active","category":"status"},{"label":"Diabetes mellitus type 2","category":"indication"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=GEMIGLIPTIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:22:35.713888+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:22:44.260438+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GEMIGLIPTIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:22:44.537363+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Dipeptidyl peptidase IV inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:22:45.582579+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3707235/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:22:45.240421+00:00"}},"allNames":"zemiglo","offLabel":[],"synonyms":["gemigliptin","zemiglo","LC15-0444"],"timeline":[{"date":"2012-06-27","type":"positive","source":"DrugCentral","milestone":"Korean Food and Drug Administration (KFDA) approval"}],"approvals":[{"date":"2012-06-27","orphan":false,"company":"","regulator":"Korean Food and Drug Administration (KFDA)"}],"brandName":"Zemiglo","ecosystem":[{"indication":"Diabetes mellitus type 2","otherDrugs":[{"name":"acarbose","slug":"acarbose","company":"Bayer Hlthcare"},{"name":"acetohexamide","slug":"acetohexamide","company":"Lilly"},{"name":"albiglutide","slug":"albiglutide","company":"Glaxosmithkline Llc"},{"name":"alogliptin","slug":"alogliptin","company":"Takeda Pharms Usa"}],"globalPrevalence":537000000}],"mechanism":{"target":"Dipeptidyl peptidase 4","targets":[{"gene":"DPP4","source":"DrugCentral","target":"Dipeptidyl peptidase 4","protein":"Dipeptidyl peptidase 4"},{"gene":"DPP9","source":"DrugCentral","target":"Dipeptidyl peptidase 9","protein":"Dipeptidyl peptidase 9"}],"modality":"Small Molecule","drugClass":"gemigliptin","explanation":"","oneSentence":"","technicalDetail":"Gemigliptin acts as a competitive inhibitor of DPP-4, preventing the breakdown of incretin hormones GLP-1 and GIP, which in turn stimulates insulin secretion and suppresses glucagon secretion from pancreatic alpha cells."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4833","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=GEMIGLIPTIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GEMIGLIPTIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:41:44.763608","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:22:46.846859+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"metformin","drugSlug":"metformin","fdaApproval":"1995-03-03","patentExpiry":"May 1, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"rosiglitazone","drugSlug":"rosiglitazone","fdaApproval":"1999-05-25","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"glimepiride","drugSlug":"glimepiride","fdaApproval":"1995-11-30","genericCount":17,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"pioglitazone","drugSlug":"pioglitazone","fdaApproval":"1999-07-15","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"sitagliptin","drugSlug":"sitagliptin","fdaApproval":"2006-10-16","patentExpiry":"Feb 25, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"alogliptin","drugSlug":"alogliptin","fdaApproval":"2013-01-25","patentExpiry":"Jun 27, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"saxagliptin","drugSlug":"saxagliptin","fdaApproval":"2009-07-31","patentExpiry":"Nov 30, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"linagliptin","drugSlug":"linagliptin","fdaApproval":"2011-05-02","patentExpiry":"Sep 5, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"gemigliptin","indications":{"approved":[{"name":"Diabetes mellitus type 2","source":"DrugCentral","snomedId":44054006,"regulator":"FDA","usPrevalence":37300000,"globalPrevalence":537000000,"prevalenceMethod":"curated","prevalenceSource":"IDF Diabetes Atlas, 2024"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"metformin","brandName":"metformin","genericName":"metformin","approvalYear":"1995","relationship":"same-class"},{"drugId":"rosiglitazone","brandName":"rosiglitazone","genericName":"rosiglitazone","approvalYear":"1999","relationship":"same-class"},{"drugId":"glimepiride","brandName":"glimepiride","genericName":"glimepiride","approvalYear":"1995","relationship":"same-class"},{"drugId":"pioglitazone","brandName":"pioglitazone","genericName":"pioglitazone","approvalYear":"1999","relationship":"same-class"},{"drugId":"sitagliptin","brandName":"sitagliptin","genericName":"sitagliptin","approvalYear":"2006","relationship":"same-class"},{"drugId":"alogliptin","brandName":"alogliptin","genericName":"alogliptin","approvalYear":"2013","relationship":"same-class"},{"drugId":"saxagliptin","brandName":"saxagliptin","genericName":"saxagliptin","approvalYear":"2009","relationship":"same-class"},{"drugId":"linagliptin","brandName":"linagliptin","genericName":"linagliptin","approvalYear":"2011","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06495281","phase":"","title":"Observational Study of Triple Combination Therapy of Zemidapa Tab. and Metformin in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"LG Chem","startDate":"2023-10-26","conditions":["Type 2 Diabetes Mellitus"],"enrollment":2044,"completionDate":"2025-12-03"},{"nctId":"NCT07399470","phase":"PHASE1","title":"A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagliflozin, and Metformin is, Compared With Taking Zemiglo and Xigduo XR Together While Fasting.","status":"ACTIVE_NOT_RECRUITING","sponsor":"LG Chem","startDate":"2026-01-09","conditions":["Healthy Volunteers","Fasting Conditions"],"enrollment":58,"completionDate":"2026-02-28"},{"nctId":"NCT07396844","phase":"PHASE1","title":"The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin in Healthy Volunteers","status":"NOT_YET_RECRUITING","sponsor":"LG Chem","startDate":"2026-07-01","conditions":["Healthy","Fasting","Fed"],"enrollment":28,"completionDate":"2026-07-31"},{"nctId":"NCT07333742","phase":"PHASE1","title":"A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metformin 50/10/1000mg is Compared to Taking Gemigliptin 50mg Separately With Dapagliflozin/Metformin 10/1000mg in Healthy Adults After a Meal","status":"COMPLETED","sponsor":"LG Chem","startDate":"2025-09-29","conditions":["Fed Conditions","Healthy Volunteer"],"enrollment":50,"completionDate":"2025-11-27"},{"nctId":"NCT06141980","phase":"PHASE3","title":"Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2023-12","conditions":["T2DM (Type 2 Diabetes Mellitus)"],"enrollment":134,"completionDate":"2025-09"},{"nctId":"NCT05194592","phase":"PHASE4","title":"Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes","status":"UNKNOWN","sponsor":"Wonju Severance Christian Hospital","startDate":"2022-01-07","conditions":["Type2 Diabetes","Remodeling, Ventricular"],"enrollment":122,"completionDate":"2025-06-30"},{"nctId":"NCT03842267","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)","status":"COMPLETED","sponsor":"LG Chem","startDate":"2019-05-13","conditions":["Diabetes Mellitus, Type 2"],"enrollment":315,"completionDate":"2022-11-30"},{"nctId":"NCT05663736","phase":"PHASE4","title":"Effect of Gemigliptin Versus Glimepiride on Cardiac Diastolic Function in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2020-01-01","conditions":["Ejection Fraction"],"enrollment":80,"completionDate":"2023-12-31"},{"nctId":"NCT05281029","phase":"","title":"Observational Study Gemigliptin in Patients Aged ≥ 65 Years With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2021-06-24","conditions":["Type 2 Diabetes Mellitus"],"enrollment":3000,"completionDate":"2023-10-31"},{"nctId":"NCT02609815","phase":"NA","title":"Initial Combination of Gemigliptin and Metformin on Microbiota Change","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-11-01","conditions":["Diabetes"],"enrollment":70,"completionDate":"2021-03-15"},{"nctId":"NCT05105698","phase":"PHASE1","title":"Food-effect Bioavailability of Gemigliptin and Dapagliflozin 50/10 mg","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2022-01-01","conditions":["Healthy Volunteers"],"enrollment":28,"completionDate":"2022-09-30"},{"nctId":"NCT04317703","phase":"PHASE1","title":"Bioequivalence Study for Fixed Dose Combination Zemimet® SR Tab. 50/1000 and Coadministration of Gemigliptin 50 mg and Metformin 1000 mg.","status":"COMPLETED","sponsor":"LG Chem","startDate":"2020-08-19","conditions":["Type 2 Diabetes"],"enrollment":40,"completionDate":"2020-09-05"},{"nctId":"NCT04705506","phase":"NA","title":"Gemigliptin and Biomarkers of Kidney Injury and Vascular Calcification","status":"COMPLETED","sponsor":"Bangkok Metropolitan Administration Medical College and Vajira Hospital","startDate":"2017-02-05","conditions":["Diabetic Nephropathies"],"enrollment":201,"completionDate":"2019-03-01"},{"nctId":"NCT04544319","phase":"PHASE1","title":"Clinical Trial to Compare the PK of the Fixed-dose Combinations and Each Component of Gemigliptin/Dapagliflozin 50/10 mg","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2020-10","conditions":["T2DM"],"enrollment":44,"completionDate":"2021-07"},{"nctId":"NCT03864432","phase":"PHASE1","title":"An Ascending Dose, Single/Multiple Dosing, Food Effect Clinical Trial to Evaluate Pharmacokinetics, Safety and Tolerability in Healthy Subjects After Oral Administration of Gemigliptin (Phase I)","status":"COMPLETED","sponsor":"LG Chem","startDate":"2019-07-02","conditions":["Type 2 Diabetes Mellitus"],"enrollment":48,"completionDate":"2020-02-28"},{"nctId":"NCT04255238","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2020-06-30","conditions":["Diabetes Mellitus, Type 2"],"enrollment":468,"completionDate":"2022-12-30"},{"nctId":"NCT04070794","phase":"PHASE1","title":"Food-effect Bioavailability of Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg Under Fed and Fasting Conditions","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2019-11-01","conditions":["Type2 Diabetes"],"enrollment":24,"completionDate":"2019-12-30"},{"nctId":"NCT04050098","phase":"PHASE1","title":"Bioequivalence Study for Gemigliptin/Metformin 50/1000 mg and Coadministration of Gemigliptin 50 mg and Metformin 1000 mg.","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2019-11-01","conditions":["Type2 Diabetes"],"enrollment":24,"completionDate":"2019-11-30"},{"nctId":"NCT03867942","phase":"PHASE1","title":"BE Study of Bilayer Combination of Gemigliptin/Rosuvastatin 50/20mg in Comparison to Monolayer Combination.","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2019-03-21","conditions":["Diabetes Mellitus, Type 2","Dyslipidemias"],"enrollment":48,"completionDate":"2019-08-31"},{"nctId":"NCT03202563","phase":"PHASE4","title":"Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study)","status":"COMPLETED","sponsor":"LG Chem","startDate":"2017-08-09","conditions":["Type 2 Diabetes Mellitus"],"enrollment":71,"completionDate":"2018-12-07"},{"nctId":"NCT02290301","phase":"","title":"An Observational Study to Evaluate Cardiovascular Outcomes of T2DM PatientsTreated With Gemigliptin","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2013-06-28","conditions":["Type 2 Diabetes Mellitus"],"enrollment":5180,"completionDate":"2017-11-30"},{"nctId":"NCT03565458","phase":"PHASE1","title":"Gemigliptin, Dapagliflozin, Empagliflozin DDI Study","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2018-04-05","conditions":["Type 2 Diabetes Mellitus"],"enrollment":48,"completionDate":"2018-12-22"},{"nctId":"NCT03355014","phase":"PHASE1","title":"BE Study of the Combinations of Gemigliptin/Metformin HCl Extended Release 50/1000mg(25/500mg x 2 Tablets) in Comparison to Each Component Administered Alone","status":"COMPLETED","sponsor":"LG Chem","startDate":"2017-12-13","conditions":["Healthy Male Volunteers"],"enrollment":70,"completionDate":"2018-01-12"},{"nctId":"NCT02831361","phase":"PHASE3","title":"Trial to Evaluate the Efficacy and Safety of Gemigliptin Compared With Placebo Added on Insulin Alone or on Insulin in Combination With Metformin in Type 2 DM (ZEUS II Study)","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2016-10-17","conditions":["Type 2 Diabetes Mellitus"],"enrollment":290,"completionDate":"2018-02-08"},{"nctId":"NCT03310749","phase":"PHASE1","title":"An Assessment of Pharmacokinetic Gemigliptin and Metformin Interactions in Healthy Mexican Volunteers","status":"COMPLETED","sponsor":"Stendhal Americas, S.A.","startDate":"2016-01-15","conditions":["Diabetes Mellitus, Type 2"],"enrollment":34,"completionDate":"2016-05-03"},{"nctId":"NCT02126358","phase":"PHASE3","title":"Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE)","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2014-05","conditions":["Type 2 Diabetes","Dyslipidemia"],"enrollment":290,"completionDate":"2016-03"},{"nctId":"NCT02343926","phase":"PHASE3","title":"Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-12","conditions":["Type 2 Diabetes Mellitus"],"enrollment":443,"completionDate":"2016-04"},{"nctId":"NCT02670070","phase":"PHASE1","title":"BE Study of the Combinations of Gemigliptin 50mg and Rosuvastatin 20mg in Comparison to Each Component Administered Alone","status":"UNKNOWN","sponsor":"LG Life Sciences","startDate":"2016-03","conditions":["Healthy"],"enrollment":37,"completionDate":"2016-06"},{"nctId":"NCT02186080","phase":"NA","title":"Effect of Gemigliptin on Metabolic Endotoxemia and Lipemia","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2014-07","conditions":["Type 2 Diabetes Mellitus"],"enrollment":10,"completionDate":"2015-07"},{"nctId":"NCT02250872","phase":"PHASE2,PHASE3","title":"Effects of DPP4 Inhibitor on Cisplatin Induced Acute Kidney Injury","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-12","conditions":["Cancer","Cisplatin Adverse Reaction"],"enrollment":182,"completionDate":"2018-06"},{"nctId":"NCT01990469","phase":"PHASE3","title":"Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2014-01","conditions":["T2DM"],"enrollment":219,"completionDate":"2015-04"},{"nctId":"NCT01968044","phase":"PHASE3","title":"A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study)","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2013-10","conditions":["Type 2 DM Patients With Moderate or Severe Renal Impairment"],"enrollment":132,"completionDate":"2015-10"},{"nctId":"NCT02670018","phase":"PHASE1","title":"BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 2000mg in Comparison to Each Component Administered Alone","status":"UNKNOWN","sponsor":"LG Life Sciences","startDate":"2015-08","conditions":["Healthy"],"enrollment":25,"completionDate":"2016-03"},{"nctId":"NCT02500329","phase":"PHASE4","title":"Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM Patients","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2014-09","conditions":["Endothelial Function","Type 2 Diabetes","Gemigliptin","Acarbose"],"enrollment":54,"completionDate":""},{"nctId":"NCT01662674","phase":"PHASE1","title":"BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2012-10","conditions":["Healthy"],"enrollment":27,"completionDate":"2013-03"},{"nctId":"NCT01787396","phase":"PHASE3","title":"Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2013-04","conditions":["Type 2 Diabetes Mellitus"],"enrollment":433,"completionDate":"2015-03"},{"nctId":"NCT01890629","phase":"PHASE4","title":"Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study)","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2013-05","conditions":["Type 2 Diabetes Mellitus"],"enrollment":69,"completionDate":"2014-08"},{"nctId":"NCT01595880","phase":"PHASE1","title":"BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 500mg in Comparison to Each Component Administered Alone","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2014-12","conditions":["Healthy"],"enrollment":29,"completionDate":"2015-01"},{"nctId":"NCT01825850","phase":"PHASE1","title":"Pharmacokinetic Drug Interaction Study Between Gemigliptin and Irbesartan After Oral Administration in Healthy Male Subjects","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2013-06","conditions":["Healthy"],"enrollment":30,"completionDate":"2014-03"},{"nctId":"NCT02004587","phase":"PHASE1","title":"Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White Volunteers","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2013-09","conditions":["Hepatic Impairment"],"enrollment":28,"completionDate":"2014-07"},{"nctId":"NCT02056600","phase":"PHASE1","title":"BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone.","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2014-03","conditions":["Healthy"],"enrollment":24,"completionDate":"2014-05"},{"nctId":"NCT02089126","phase":"PHASE3","title":"Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"LG Life Sciences","startDate":"2014-06","conditions":["Type 2 Diabetes Mellitus"],"enrollment":230,"completionDate":""},{"nctId":"NCT01747083","phase":"PHASE1","title":"Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets)","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2013-01","conditions":["Type 2 Diabetes"],"enrollment":24,"completionDate":"2013-04"},{"nctId":"NCT01823133","phase":"PHASE1","title":"Study for Investigate the Pharmacokinetic Drug Interactions Between Gemigliptin and Rosuvastatin","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2013-04","conditions":["Healthy"],"enrollment":30,"completionDate":"2013-08"},{"nctId":"NCT01768455","phase":"PHASE1","title":"Pharmacokinetic Drug Interaction Study Between Gemigliptin and Glimepiride in Healthy Male Subjects","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2013-02","conditions":["Healthy"],"enrollment":27,"completionDate":""},{"nctId":"NCT01603238","phase":"PHASE1","title":"Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C] LC15-0444","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2011-05","conditions":["Healthy"],"enrollment":6,"completionDate":"2011-07"},{"nctId":"NCT01602003","phase":"PHASE3","title":"Phase III Trial to Evaluate the Efficacy and Safety of LC15-0444 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2009-12","conditions":["Type 2 Diabetes Mellitus"],"enrollment":425,"completionDate":"2012-05"},{"nctId":"NCT01601990","phase":"PHASE3","title":"Phase 3 Trial to Evaluate the Efficacy and Safety of LC15-0444 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2009-12","conditions":["Type 2 Diabetes Mellitus"],"enrollment":189,"completionDate":"2011-11"},{"nctId":"NCT01426399","phase":"PHASE1","title":"Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of LC15-0444 and Metformin After Oral Administration in Healthy Male Subjects","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2011-08","conditions":["Healthy"],"enrollment":30,"completionDate":"2011-12"},{"nctId":"NCT01426906","phase":"PHASE1","title":"Pharmacokinetic Drug Interaction Study in Healthy Male Subjects","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2011-01","conditions":["Healthy Male Volunteers"],"enrollment":24,"completionDate":"2011-03"},{"nctId":"NCT01001013","phase":"PHASE1","title":"Pharmacokinetic Drug Interaction Between LC15-0444 and Pioglitazone After Oral Administration in Healthy Male Subjects","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2009-02","conditions":["Healthy"],"enrollment":24,"completionDate":"2009-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"5DHU18M5D6","CHEBI":"CHEBI:134731","INN_ID":"9291","UMLSCUI":"C3501981","chemblId":"CHEMBL3707235","ChEMBL_ID":"CHEMBL3707235","KEGG_DRUG":"D10502","DRUGBANK_ID":"DB12412","PUBCHEM_CID":"11953153","MESH_SUPPLEMENTAL_RECORD_UI":"C534891"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":98,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"A10BD18","allCodes":["A10BD18","A10BH06","A10BH52"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Dec","pmid":"41804593","title":"Effect of anti-tuberculosis drugs on the pharmacokinetics and pharmacodynamics of novel antidiabetic drugs: A scoping review.","journal":"Pulmonology"},{"date":"2025 Dec 1","pmid":"41327925","title":"Gemigliptin Alleviates Succinate Induced Endoplasmic Reticulum Stress and Activation of Hepatic Stellate Cells.","journal":"Journal of Korean medical science"},{"date":"2025 Oct","pmid":"41084226","title":"Pharmacokinetics and Safety of Fixed-Dose Versus Separate Enavogliflozin/Gemigliptin Combinations, and Food Effect on Enavogliflozin in Healthy Korean Subjects.","journal":"Clinical and translational science"},{"date":"2025 Sep 1","pmid":"40633785","title":"Repositioning gemigliptin for the alleviation of thioacetamide-induced liver fibrosis in rats: Targeting TLR4/MAPK, SIRT1/AMPK/Nrf2, PI3K/AKT/mTOR axis and apoptosis.","journal":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences"},{"date":"2025 Apr","pmid":"39910751","title":"Effectiveness of gemigliptin on risk of major adverse kidney events in people with type 2 diabetes: A Korean cohort study.","journal":"Diabetes, obesity & metabolism"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":2,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"Korean Food and Drug Administration (KFDA)","status":"approved","approval_date":"2012-06-27T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:22:46.846859+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}